Skip to main content
Fig. 1 | Cancer Imaging

Fig. 1

From: Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments

Fig. 1

PFS in the full EP by (A) number of extranodal sites*, (B) bone involvement by PET/CT and (C) baseline bone marrow biopsy and bone involvement by PET/CT, and (D) CNS relapse by the model incorporating imaging metrics and CNS-IPI. *Extranodal involvement was estimated by combining tumor masses in the lungs, liver, spleen, and bone tumor involvement. BMB, bone marrow biopsy; CI, confidence interval; CNS, central nervous system; CNS-IPI, CNS International Prognostic Index; CT, computed tomography; EP, evaluable population; IPI, International Prognostic Index; HR, hazard ratio; PET, positron-emission tomography; PFS, progression-free survival

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us